Novo Nordisk’s next-generation obesity treatment shows promise in early study
A new weight loss drug from Novo Nordisk helped patients lose a large amount of weight, providing a boost for Novo in the competitive field.
Novo Nordisk Shares Surge on New Obesity Drug Results
Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial.
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to develop new treatments for cardiometabolic diseases using human data and artificial intelligence (AI).
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to be more efficient than its blockbuster drugs currently on the market, Ozempic and Wegovy.
Novo Nordisk Jumps On Experimental Weight-Loss Drug Trial Results
Novo Nordisk reported strong early-stage results for its once-a-week obesity drug. Early Friday, Novo Nordisk stock jumped. Eli Lilly fell.
Next-gen Novo Nordisk shot shows 22% weight loss in early results
One of Novo Nordisk's next-generation obesity shots to follow up on its success with Wegovy helped patients lose 22% of their weight in 36 weeks, according to early-stage trial results on Friday, boosting the drugmaker's shares.
Novo Nordisk shares pop 10% on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk, Valo Health Expand Drug Discovery and Development Pact
Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence.The deal extends ...
pharmaphorum15d
Novo Nordisk swells alliance with AI firm Valo Health
Novo Nordisk has almost doubled the scale of an R&D alliance with Valo Health – a specialist in applying artificial ...
PMLiVE8d
Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases
Novo Nordisk and Valo Health have expanded their agreement to discover and develop new treatments for type 2 diabetes, ...
Business Insider16d
Valo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Novo Nordisk and Valo plan to continue working closely together to derive novel insights from human genetic and longitudinal patient data at the intersection of obesity, type 2 diabetes, and ...
Ozempic maker Novo Nordisk, after trial disappointment, expands AI deal in potential $4.6 billion pact
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
Daily12d
Novo Nordisk, Valo Health expand collaboration to discover, develop novel treatments for cardiometabolic diseases
Lexington: Novo Nordisk A/S and Valo Health, Inc. have announced they have entered into an expanded agreement to discover and ...
Novo Nordisk, Valo Health expand drug discovery collaboration
Novo Nordisk A/S and Valo Health, Inc. today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, ty ...
Why Viking Therapeutics Stock Popped, but Novo Nordisk and Hims & Hers Health Dropped Today
In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...